FRX Forest Road Acquisition Corp

Preliminary Results Support Continuation of Development Program NEW YORK, Sept. 28 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) and Cypress Bioscience, Inc. (NASDAQ:CYPB) today announced that preliminary top-line results from an 888 patient randomized, double-blind, placebo-controlled pivotal Phase III study support the continued development of milnacipran as a treatment for fibromyalgia (FMS). Although the results did not achieve statistical significance at the p